1. Show article details.

    Spectrum Pharma to seek cancer drug approval in 3rd qtr

    Reuters – 11:58 AM ET 04/23/2014

    * Analysts expect approval next year. * Shares rise as much as 7 pct. By Natalie Grover. Spectrum Pharmaceuticals Inc (SPPI) said it expects to seek U.S. marketing approval for its blood cancer drug in the third quarter, after the treatment was shown to be safe and effective in a key mid-stage trial. The company's shares rose up as much as 7 percent on Wednesday.

  2. Show article details.

    Spectrum Pharma's cancer drug meets main goal in trial

    Reuters – 7:26 AM ET 04/23/2014

    Spectrum Pharmaceuticals (SPPI) said its experimental cancer drug was shown to be safe and effective in a mid-stage trial. Spectrum's drug, Captisol-enabled melphalan, is an intravenous formulation of a common chemotherapy drug melphalan, and is being tested in multiple myeloma patients undergoing stem cell transplants. The company said it expects to file for a regulatory approval in the third quarter.

  3. Show article details.

    Ligand’s Partner Spectrum Pharmaceuticals Reports Captisol-Enabled Melphalan Meets Primary Endpoint in Pivotal Trial

    Business Wire – 7:10 AM ET 04/23/2014

    Ligand Pharmaceuticals Incorporated (LGND) announces that its Captisol-enabled™ Melphalan development and commercial partner Spectrum Pharmaceuticals (SPPI) has reported that their pivotal trial of CE Melphalan met its primary endpoint.

  4. Show article details.

    Spectrum Pharmaceuticals’ Pivotal Trial of Captisol-Enabled™ (Propylene Glycol-Free) Melphalan Meets Primary Endpoint

    Business Wire – 7:00 AM ET 04/23/2014

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its pivotal trial of Captisol-enabled™ Melphalan met its primary end points.

  5. Show article details.

    Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer

    Business Wire – 7:00 AM ET 04/21/2014

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the promotion of Joseph Turgeon to President and Chief Operating Officer.

  6. Show article details.

    Analysts View on Biotech Equities -- Research on Organovo Holdings, BioMarin Pharma, Vertex Pharma, and Spectrum Pharma

    PR Newswire – 11:15 AM ET 04/15/2014

    LONDON, April 15, 2014 On Monday, April 14, 2014, the NASDAQ Composite ended at 4,022.69, up 0.57%, the Dow Jones Industrial Average advanced 0.91%, to finish the day at 16,173.24, and the S&P 500 closed at 1,830.61, up 0.82%. The gains were broad based as all the sectors ended the session in positive. SOURCE Investor-Edge.

  7. Show article details.

    Is biotech caught in a bubble, and is it popping?

    MarketWatch – 1:13 PM ET 04/08/2014

    Confused investors looking for advice on where biotechnology stocks are headed might get a clue from the head of one company in the sector. Rajesh C. Shrotriya, chairman and chief executive of Spectrum Pharmaceuticals (SPPI), says with conviction that a lot of biotech shares are overvalued because, simply put, they've been "selling a dream" instead of focusing on fundamentals. Shrotriya stops short of declaring the current state of affairs a "bubble," though he understands why some...

  8. Show article details.

    Biotech Stocks Technical Review -- Research on BioCryst Pharma, Spectrum Pharma, BioMarin Pharma, and Vertex Pharma

    PR Newswire – 11:55 AM ET 03/26/2014

    LONDON, March 26, 2014 On Tuesday, March 25, 2014, the NASDAQ Composite ended at 4,234.27, up 0.19%, the Dow Jones Industrial Average advanced 0.56% to 16,367.88, and the S&P 500 closed at 1,865.62, up 0.44%. The gains were broad based as nine out of 10 sectors ended the session in positive. SOURCE Investor-Edge.

  9. Show article details.

    Spectrum Pharmaceuticals to Present Corporate Update at the 26th Annual ROTH Conference in Laguna Niguel on March 11th

    Business Wire – 7:00 AM ET 03/07/2014

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the 26th Annual ROTH Conference being held at The Ritz-Carlton Hotel in Laguna Niguel, California.

  10. Show article details.

    Spectrum Pharmaceuticals Reports Fourth and Full Year 2013 Financial Results

    Business Wire – 4:00 PM ET 03/06/2014

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period and year ended December 31, 2013.

  11. Show article details.

    Spectrum Pharmaceuticals Announces Fourth Quarter 2013 Financial Results Teleconference and Webcast

    Business Wire – 4:05 PM ET 02/27/2014

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the fourth quarter 2013 financial results, provide an update on the Company's business, and discuss expectations for the future.

  12. Show article details.

    Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for Beleodaq™ (belinostat) for Injection, a novel pan-HDAC inhibitor

    Business Wire – 7:00 AM ET 02/06/2014

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, announced today that its New Drug Application for Beleodaq, a novel, pan-histone deacetylase inhibitor, has been accepted for filing by the U.S. Food and Drug Administration.

Page:

Today's and Upcoming Events

  • May
    8

    SPPI to announce Q1 earnings Unspecified (Unconfirmed)

  • Jun
    27

    Shareholders Meeting

Past Events (last 90 days)

  • Mar
    6

    SPPI Earnings Conference Call at 4:30 PM Listen

Data provided by Wall Street Horizon, Inc. © 2014

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.